EE55 Cost-Effectiveness of ESMO-Recommended Lenvatinib and Pembrolizumab Regimen as Second-Line Treatment for Advanced Endometrial Carcinoma in Taiwan: A Comparison With NCCN Recommendations
Abstract
Authors
C.H. Chueh P.K. Ho S.T. Chiang Y.W. Wen Shiu M.N. J.H. Liu W.H. Li Y.W. Tsai